布地奈德与特布他林联合雾化吸入辅助治疗肺炎支原体肺炎的疗效分析

Analysis of the Efficacy of Budesonide Combined with Terbutaline Inhalation in the Adjuvant Treatment of Mycoplasma Pneumonia

目的 分析布地奈德与特布他林联合雾化吸入辅助治疗肺炎支原体肺炎的疗效。方法 回顾性选取2022年1月—2023年10月德化县医院收治的86例肺炎支原体肺炎患儿的临床资料,按不同治疗方法分为治疗组(阿奇霉素联合布地奈德与特布他林雾化吸入)、对照组(阿奇霉素),各43例。分析两组患儿治疗后疗效、症状消失时间以及血清C反应蛋白和白细胞水平。结果 治疗组患儿临床总治疗有效率为93.02%(40/43),高于对照组的83.72%(36/43),差异有统计学意义(χ^(2)=4.208,P<0.05)。治疗组患儿发热、咳嗽、肺部啰音的消失时间为(3.91±1.81)d、(6.53±1.56)d、(6.33±2.60)d,均短于对照组的(4.79±1.47)d、(7.88±2.16)d、(7.56±2.44)d,差异有统计学意义(t=2.483、3.314、2.267,P均<0.05)。治疗后治疗组患儿血清C反应蛋白和白细胞水平均低于对照组,差异有统计学意义(P均<0.05)。结论 肺炎支原体肺炎治疗中采取特布他林雾化吸入辅助治疗能更快缓解症状,提高临床疗效,减轻体内炎症状态。

Objective To analyze the efficacy of budesonide combined with terbutaline inhalation in the treatment of mycoplasma pneumonia.Methods The clinical data of 86 children with mycoplasma pneumoniae pneumonia admitted to Dehua County Hospital from January 2022 to October 2023 were retrospectively selected.They were divided into treatment group(azithromycin combined with budesonide and terbutaline atomization inhalation)and control group(azithromycin)according to different treatment methods,with 43 cases in each group.The efficacy,symptom disappearance time,the level of serum C-reactive protein and white blood cell in children in two groups after treatment were analyzed.Results The total effective rate of clinical treatment in the treatment group was 93.02%(40/43),which was higher than 83.72%(36/43)in the control group,and the difference was statistically significant(χ^(2)=4.208,P<0.05).The disappearance time of fever,cough and pulmonary rales in the treatment group were(3.91±1.81)d,(6.53±1.56)d and(6.33±2.60)d,which were all shorter than(4.79±1.47)d,(7.88±2.16)d and(7.56±2.44)d in the control group,and the differences were statistically significant(t=2.483,3.314,2.267,all P<0.05).After treatment,the levels of serum C-reactive protein and white blood cells in the treatment group were lower than those in the control group,and the differences were statistically significant(both P<0.05).Conclusion Terbutaline aerosol inhalation adjuvant therapy in the treatment of mycoplasma pneumoniae pneumonia can relieve symptoms faster,improve clinical efficacy,and reduce inflammation in the body.